CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel
Commercial payers pay $613 on average nationally for this procedure.
CPT code 81413 describes a genomic sequencing panel service in which a laboratory analyst performs all technical steps to analyze DNA for genetic variants across a panel of at least 10 genes associated with cardiac ion channelopathies, a group of disorders affecting the heart’s electrical signaling; the service is a targeted genomic sequence analysis panel (DNA) typically performed in a clinical molecular genetics or pathology laboratory as an outpatient or reference lab test on patient specimens.
Customize your policy alerts
Sign up for cpt 81413 policy alerts
Get alerted when payer policies referencing 81413 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial rates for CPT 81413 cluster around BUCA’s average commercial benchmark of $613.30, with substantial variation among national payers. Blue Cross Blue Shield shows the highest dispersion and upper-end rates, with a broad spread between $472.70 (P25) and $776.20 (P75) and a max outlier at $2,346.10, while Cigna and UnitedHealth Group also present high ceilings of $2,654.00 and $2,165.30 respectively. Aetna’s central tendency is lower, with a mean of $417.90 and median of $456.20, sitting nearer BUCA’s midpoint than the highest-pay insurers.
Measure of interquartile dispersion (P75 minus P25) highlights which payers are tightest or widest: Aetna’s range is $258.60, UnitedHealth Group’s is $318.30, BUCA’s is $382.20, Blue Cross Blue Shield’s is $289.50, and Cigna’s is $494.50. Cigna exhibits the widest IQR at $494.50, indicating the greatest mid-market variability, while Aetna is the tightest at $258.60, suggesting the most concentrated middle distribution among these commercial payers.